**Supplementary Material**

**Supplementary table 1**: Number of patients and episodes analyzed.

|  |  |  |
| --- | --- | --- |
| Patientsn = 445 | DOAC per patient (n) | Episodesn = 490 |
| 4034011 | 1234 | 403  80  3 4 |

**Supplementary table 2**: Description of dose adjustments and crossover between DOACs.

|  |  |  |
| --- | --- | --- |
|  | **Number switching** | **New DOAC prescribed** |
| DOAC | no. |
| Total | 42/445 (9,4%) |  |  |
| Rivaroxaban | 16/165 (9.7%) |  |  |
|  Rivaroxaban 20 mg | 12/87 (13,8%) | R15A5D110 | 741 |
|  Rivaroxaban 15 mg | 4/78 (5,1%) | A2.5A5R20 | 211 |
| Dabigatran | 21/154 (13,6%) |  |  |
|  Dabigatran 150 mg | 11/96 (11,4%) | A5R20D110 | 533 |
|  Dabigatran 110 mg | 8/55 (14.5%) | A2.5A5D150R15 | 4211 |
|  Dabigatran 75 mg | 2/3 (66,6%) | D110 | 2 |
| Apixaban | 5/126 (3.9%) |  |  |
|  Apixaban 5 mg | 5/92 (5.4%) | A2.5R15 | 41 |
|  Apixaban 2.5 mg | 0/34 (0%) |  |  |

Only patients with the first dose adjustment or DOAC cross-over are shown.

(One patient switched 3 times: D150 => D110 => A5 => A2.5 and another patient switched twice: D75 => D110 => A2.5).

**Supplementary table 3**: Rate of appropriate dosing.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Apixaban | Dabigatran | Rivaroxaban | total |
| Appropriate dose | 122 (80.8%) | 135 (83.8) | 116 (65.2%) | 373 (76%) |
| Inappropriate dose Low dose High dose | 28 (18.5%)1 (0.9%) | 24 (14.9%)2 (1.2%) | 56 (31.4%)6 (3.4%) | 108 (22%)9 (1.8%) |

**Supplementary table 4**: Rates of thromboembolic events by study group

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Apixaban2.5 mg(n=46) | Apixaban5 mg(n=105) | Dabigatran110 mg(n=61) | Dabigatran150 mg(n=97) | Rivaroxaban15 mg(n=87) | Rivaroxaban20 mg(n=91) | Dabigatran75 mg*(n=3)* | **Total****(n=490)** |
|  | Patientsn | n/100Pt-Yr | Patientsn | n/100Pt-Yr | Patientsn | n/100Pt-Yr | Patientsn | n/100Pt-Yr | Patientsn | n/100Pt-Yr | Patientsn | n/100Pt-Yr | Patientsn | n/100Pt-Yr | Patientsn | n/100Pt-Yr |
| Total - Stroke - TIA | 101 | 1.2601.26 | 431 | 2.071.550.52 | 440 | 3.673.670 | 220 | 1.131.130 | 862 | 4.63.451.15 | 000 | 000 | 101 | 24.14024.14 | 20155 | 2.181.640.54 |

Abbreviations: Pt-Yr = number of events per 100 patients-years of follow-up; TIA = transient ischemic attack.

Data are shown for treatment episodes with one or more events (one patient on rivaroxaban 15 mg suffered a TIA and subsequently a stroke).

No systemic thromboembolisms were observed.

**Supplementary table 5**: Rates of major and non-major clinically relevant (NMCR) bleeding events by study group.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Apixaban2.5 mg(n=46) | Apixaban5 mg(n=105) | Dabigatran110 mg(n=61) | Dabigatran150 mg(n=97) | Rivaroxaban15 mg(n=87) | Rivaroxaban20 mg(n=91) | Dabigatran75 mg*(n=3)* | **Total****(n=490)** |
| n | n/100Pt-Yr | n | n/100Pt-Yr | n | n/100Pt-Yr | n | n/100Pt-Yr | n | n/100Pt-Yr | n | n/100Pt-Yr | n | n/100Pt-Yr | n | n/100Pt-Yr |
| incidence rate of a first major and NMCR bleeding event | 2 | (2,5) | 11 | (5,7) | 10 | (9,2) | 13 | (7,4)  | 9 | (5.2) | 12 | (6,6) | 0 | (0) | 57 | (6,2) |
| Incidence rate of any major and NMCRbleeding eventa | 5 | (6.3) | 12 | (6.2) | 11 | (10.1) | 15 | (8,5) | 9 | (5,2) | 16 | (8.7) | 0 | (0) | 68 | (7,4) |
|  Major bleeding NMCR bleeding | 41 | (5)(1.3) | 48 | (2.1)(4.1) | 29 | (1.8)(8.3) | 411 | (2.3)(6.2) | 63 | (3.5)(1.7) | 214 | (1.1)(7.6) | 00 | (0)(0) | 2246 | **(2.4)****(5)** |
|  Location |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Gastrointestinal | Total Major NMCR | 5\*41 | (6.3)(5)(1.3) | 321 | (1.5)(1.1)(0.5) | 514 | (4.6)(0.9)(3.7) | 431 | (2.3)(1.7)(0.6) | 321 | (1.7)(1.1)(0.6) | 422 | (2.2)(1.1)(1.1) | *-**-**-* | *-**-**-* | 241410 | (2.6)(1.5)(1.1) |
|  Genitourinary | Total Major NMCR | --- | --- | 2\*-2 | (1.1)-(1.1) | 413 | (3.7)(0.9)(2.7) | 6\*-6 | (3.4)-(3.4) | 1-1 | (0.6)-(0.6) | 6\*-6 | (3.3)-(3.3) | *-**-**-* | *-**-**-* | 19118 | (2.1)(0.1)(1.9) |
|  Cranial | Total (all major) | - | - | 2\* | (1.1) | - | - | - | - | 3\* | (1.7) | - | - | *-* | *-* | 5 | (0.5) |
|  Epistaxis | Total (all NMCR) | - | - | 3 | (1.5) | - | - | 1 | (0.6) | - | - | - | - | *-* | *-* | 4 | (0.4) |
|  Hemoptysis | Total (all NMCR) | - | - | - | - | - | - | 1 | (0.6) | - | - | 3 | (1.6) | *-* | *-* | 4 | (0.4) |
|  Muscular | Total (all NMCR) | - | - | - | - | 1 | (0.9) | - | - | 1 | (0.6) | - | - | *-* | *-* | 2 | (0.2) |
|  Conjunctival | Total (all NMCR) | - | - | 1 | (0.5) | - | - | 1 | (0.6) | - | - | - | - | *-* | *-* | 2 | (0.2) |
|  Gingivorrhagia | Total (all NMCR) | - | - | - | - | - | - | 1 | (0.6) | - | - | 1 | (0.5) | *-* | *-* | 2 | (0.2) |
|  Ecchymosis | Total (all NMCR) | - | - | - | - | 1 | (0.9) | - | - | - | - | - | - | *-* | *-* | 1 | (0.1) |
|  Other | Total (all NMCR) |  |  | 1 | (0.5) |  |  | 1 | (0.6) |  |  | 2 | (1.1) |  |  | 5 | (0.5) |

A dash (-) represents that there were no patients with events.

a. Several events, when they occur, are counted in the same episode within the period under study (5 patients each experienced 2 major/NMCR bleedings, 1 patient experienced 3 major/NMCR bleedings and 1 patient experienced 4 major/NMCR bleedings during the study period).

\* Includes patients with repeated events for episode in the same location due to an underlying bleeding pathology e.g. radiation proctitis and bladder, uterine or prostate cancer.

**Supplementary guide: Guide/Protocol for using DOACs developed at the Hospital.**

**Sagunto.san.gva.es/documents/7967159/7992985/guia\_nacos.pdf**